Evidence map›Paper›PMID 41066601›Full record

ArticlePLoS neglected tropical diseases2025

Piloting the Schistosomiasis Practical and Precision Assessment approach in five health districts of the N'zérékoré region, Republic of Guinea.

Balla Moussa Keita, Mamadou Diallo, Mariam Diarra, Souleymane Traore, Antoine Tamba Kamano, Dienabou Keita, Ablam Amento, Moussa Sylla, N'falaye Kante, Alber Dopavogui and 9 more

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Balla Moussa KeitaHealth and Sustainable Development Foundation (FOSAD) in French, Conakry, Guinea.ORCID 0000-0002-6469-2830
Mamadou DialloHealth and Sustainable Development Foundation (FOSAD) in French, Conakry, Guinea.
Mariam DiarraNational Program for the Fight Against Neglected Tropical Diseases with Preventive Chemotherapy (PNL-MTN-CTP), Conakry, Guinea.
Souleymane TraoreHealth and Sustainable Development Foundation (FOSAD) in French, Conakry, Guinea.
Antoine Tamba KamanoNational Program for the Fight Against Neglected Tropical Diseases with Preventive Chemotherapy (PNL-MTN-CTP), Conakry, Guinea.
Dienabou KeitaHealth and Sustainable Development Foundation (FOSAD) in French, Conakry, Guinea.
Ablam AmentoHealth and Sustainable Development Foundation (FOSAD) in French, Conakry, Guinea.
Moussa SyllaMafrinyah Rural Health Training and Research Center, Mafrinyah, Guinea.
N'falaye KantePolyclinique Communautaire Moderne (PCM), Dubreka, Guinea.
Alber DopavoguiPolyclinique Communautaire Moderne (PCM), Dubreka, Guinea.
Cheick Mouctar SyllaPolyclinique Communautaire Moderne (PCM), Dubreka, Guinea.
Sekou BereteHealth and Sustainable Development Foundation (FOSAD) in French, Conakry, Guinea.
Penelope VounatsouSwiss Tropical and Public Health Institute, Allschwil, Switzerland.
Stella KephaKenya Medical Research Institute, Nairobi, Kenya.
Katherine GassTask Force for Global Health, Decatur, Georgia, United States of America.
Rachel L PullanLondon School of Hygiene and Tropical Medicine, London, United Kingdom.
Fiona M FlemingUnlimit Health, London, United Kingdom.
Nouhou Konkoure DialloNational Program for the Fight Against Neglected Tropical Diseases with Preventive Chemotherapy (PNL-MTN-CTP), Conakry, Guinea.
Mandy Kader KondeHealth and Sustainable Development Foundation (FOSAD) in French, Conakry, Guinea.

Funding

Bill & Melinda Gates FoundationUnited States Agency for International Development (USAID)
6 · The paper itself

Abstract

backgroundIn Guinea, N'Zérékoré region has historically been endemic for both Schistosoma mansoni and S. haematobium. Following eight years of mass treatment with praziquantel to treat schistosomiasis, as part of a multi-country project, the country was selected to pilot the Schistosomiasis Practical and Precision Assessment (SPPA) approach. The SPPA pilot was conducted in five health districts in the forest region. The main objectives were to determine the current infection status and treatment strategy for each health sub-district and to evaluate the feasibility of the SPPA approach. METHODOLOGY/PRINCIPAL

findingsA cross-sectional study among children aged 10-14 years of age was conducted. In each health district, a systematic sample of 15 schools were selected with 32 school children selected randomly from each. Stool and urine samples were collected from each child. Two Kato-Katz slides were examined for S. mansoni and soil transmitted helminthiasis (STH) and one urine filtration slide and one hemastix for S. haematobium infections and microhaematuria, respectively. Of the 2400 children targeted for inclusion, 2325 provided samples (96.9%). The combined prevalence of Schistosoma species across the five health districts was 66.4%. S. mansoni had a high prevalence of 66.1% with four health districts above 50%. S. haematobium had a low prevalence of 4.3%. The overall prevalence of any combined STH (Ascaris lumbricoides, Trichuris trichiura or hookworm) was 11.7%. Sex, age and contact with a freshwater body during the last week before the survey, were not statistically significant in their association with schistosomiasis.

conclusionThe results of the SPPA indicate that schistosomiasis remains homogeneously high across all five health districts. Consequently, it is recommended to maintain annual treatment in each sub-health district, and to extend treatment to whole communities aged two years of age and over, while strengthening critical cross-sectoral interventions such as behaviour change and environmental management.

Indexed as

SchistosomiasisSchistosomiasis mansoniAdolescentAnimalsAnthelminticsChildCross-Sectional StudiesFecesFemaleGuineaHumansMalePilot ProjectsPraziquantelPrevalenceSchistosoma haematobiumAnthelminticsPraziquantel

Identifiers

PMID41066601
PMCPMC12517497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.